Verve Therapeutics, Inc.
VERV
$5.76
-$0.02-0.35%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 32.33M | 24.40M | 20.65M | 16.05M | 11.76M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 32.33M | 24.40M | 20.65M | 16.05M | 11.76M |
| Cost of Revenue | 22.85M | 30.29M | 24.12M | 20.39M | 19.13M |
| Gross Profit | 9.48M | -5.89M | -3.47M | -4.34M | -7.37M |
| SG&A Expenses | 56.65M | 54.83M | 52.68M | 51.55M | 49.94M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 260.99M | 250.94M | 242.61M | 237.76M | 234.88M |
| Operating Income | -228.66M | -226.54M | -221.97M | -221.71M | -223.12M |
| Income Before Tax | -198.36M | -196.72M | -192.38M | -196.45M | -199.79M |
| Income Tax Expenses | 349.00K | 308.00K | 271.00K | 381.00K | 275.00K |
| Earnings from Continuing Operations | -198.71 | -197.03 | -192.65 | -196.83 | -200.07 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -198.71M | -197.03M | -192.65M | -196.83M | -200.07M |
| EBIT | -228.66M | -226.54M | -221.97M | -221.71M | -223.12M |
| EBITDA | -221.91M | -219.97M | -215.68M | -215.75M | -217.67M |
| EPS Basic | -2.35 | -2.46 | -2.60 | -2.88 | -3.13 |
| Normalized Basic EPS | -1.46 | -1.54 | -1.62 | -1.79 | -1.95 |
| EPS Diluted | -2.35 | -2.46 | -2.60 | -2.88 | -3.13 |
| Normalized Diluted EPS | -1.46 | -1.54 | -1.62 | -1.79 | -1.95 |
| Average Basic Shares Outstanding | 338.87M | 321.66M | 300.24M | 277.97M | 256.62M |
| Average Diluted Shares Outstanding | 338.87M | 321.66M | 300.24M | 277.97M | 256.62M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |